Press Release

GCTx featured by Harvard Medical School

December 2020

“Our technology allows us to discover novel cell-differentiation recipes and make practically any cell type in the body, including those that have not been made before,” said Alex Ng, co-first author with Parastoo Khoshakhlagh

GCTx technology published in Nature Biotechnology

November 2020

GCTx founders co-authored with other distinguished US and international scientists "A comprehensive library of human transcription factors for cell fate engineering" published in the November 2020 issue of Nature Biotechnology

Harvard Medical School article features GCTx

April 2020

Harvard Medical School describes how GCTx is tackling COVID-19 utilizing our TFome cell engineering technology

Biogen awarded GCTx Golden Ticket

January 2020

Biogen awarded GCTx Golden Tickets, which provide lab space at Lab Central

GCTx was featured on CBS 60 Minutes

December 2019 

CBS 60 Minutes featured our synthetic biology-based cell therapy platform technology

Nature Biotechnology highlighted GCTx in their news feature

December 2019

 Nature Biotechnology featured GCTx as a successful startup

 Amgen awarded GCTx Golden Ticket

December 2019

Amgen awarded GCTx Golden Tickets, which provide lab space at Lab Central (Cambridge, MA) and access to Amgen’s expertise in drug development

GCTx selected as one of the winners of YEi Start in France

Announced November 2019 

YEi Start in France is an accelerator program for science-based startup companies

Meet the Winners of Harvard Innovation Lab’s Presidential Challenge

May 2019

“The people who want to change the world are people who want to keep moving,” said Harvard President Lawrence Bacow during the ceremony

GCTx named a finalist for the Harvard Innovation Lab’s 2019 President’s Innovation Challenge

April 2019 

“The teams competing in this year’s President’s Innovation Challenge (PIC) represent the extraordinary talent that exists across the University,” said Harvard President Lawrence Bacow

GCTx: Revolutionizing cell therapy by building a cell engineering platform that is 100 times faster and 10 times more efficient, enabling customized therapeutics tailored to target hard-to-cure diseases